Cellectis S.A.

CLLSNASDAQHealthcare● Active

$2.93

$-0.13(-4.25%)

Market Cap$294222138

P/E Ratio—

52W High$5.48

52W Low$1.327

Avg Volume41K

Open$2.97

Beta2.75

Forecast Market Cap PE Ratio

Cellectis S.A.（CLLS）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

clls · 股价预测 · 17 位分析师（近3月）· FMP · 更新于 2026年6月8日

分析师评级与共识

基于过去 3 个月内 17 位华尔街分析师

Buy

17 位分析师

共识

评级分布

Strong Buy

Buy

Hold

Sell

Strong Sell

合计: 17 · 买入占比: 82.4%

12 个月目标价

High

$9.00

Consensus

$9.00

+207.2% upside

Low

$9.00

Median: $9 · Last Close: $2.93

Cellectis S.A.（CLLS）的分析师共识为 Buy，基于过去 3 个月内 17 位华尔街分析师的评级。CLLS 的 12 个月平均目标价为 $9.00，相对当前价 $2.93 代表 +207.2% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

算法生成 · 每日更新

Date	Predicted Price	Change	Min	Max
2026-06-09	$2.78	↓ 5.00%	$2.77	$2.80

1-day model range: $2.77–$2.8. Peak: $2.8 (-5.00%).

长期股价预测

年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031

Year	Low	Avg Price	High	Change
2027	$1	$1	$2	-50.0%
2028	$1	$1	$1	-62.5%
2029	$1	$1	$1	-67.2%
2030	$1	$1	$1	-69.2%
2031	$1	—	$1	-70.2%

Confidence:Medium

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

Market Sentiment

BEARISH

Based on 14 technical indicators

7%0%93%

1Buy

0Neutral

13Sell

RSI (14)18.1Oversold

MACDBEARISH

Refreshes daily from EOD close

Moving Averages · CLLS · Jun 8, 2026

Simple Moving Average (SMA)

MA 5$3.12SELL

MA 10$3.35SELL

MA 20$3.58SELL

MA 50$3.70SELL

MA 100$3.74SELL

MA 200$3.80SELL

Current $CLLS · Price above MA = BUY signal

Exponential Moving Average (EMA)

EMA 5$3.12SELL

EMA 10$3.28SELL

EMA 20$3.47SELL

EMA 50$3.64SELL

EMA 100$3.71SELL

EMA 200$3.54SELL

Current $CLLS · Price above MA = BUY signal

How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:

Date	Brokerage	Action	Rating
2026-04-14	Citizens	Maintains	Market Outperform→Market Outperform
2025-10-17	Barclays	Maintains	Overweight→Overweight
2025-05-13	Barclays	Maintains	Overweight→Overweight
2024-11-05	Barclays	Maintains	Overweight→Overweight
2024-06-12	Oppenheimer	Maintains	Outperform→Outperform
2024-05-31	JMP Securities	Maintains	Market Outperform→Market Outperform
2023-11-01	JMP Securities	Maintains	Market Outperform→Market Outperform
2023-08-08	Oppenheimer	Maintains	Outperform→Outperform
2023-08-07	JMP Securities	Maintains	Market Outperform→Market Outperform
2023-04-05	Citigroup	Maintains	Buy→Buy

Citizens2026-04-14

Maintains

Market Outperform→Market Outperform

Barclays2025-10-17

Maintains

Overweight→Overweight

Barclays2025-05-13

Maintains

Overweight→Overweight

Barclays2024-11-05

Maintains

Overweight→Overweight

Oppenheimer2024-06-12

Maintains

Outperform→Outperform

JMP Securities2024-05-31

Maintains

Market Outperform→Market Outperform

JMP Securities2023-11-01

Maintains

Market Outperform→Market Outperform

Oppenheimer2023-08-08

Maintains

Outperform→Outperform

JMP Securities2023-08-07

Maintains

Market Outperform→Market Outperform

Citigroup2023-04-05

Maintains

Buy→Buy

Wall Street analysts have recently issued updated ratings on Cellectis S.A. (CLLS) stock. Of the recent 40 rating actions, 3 were upgrades and 5 were downgrades. 17 analysts currently cover CLLS.

分析师推荐趋势

Buy ratings1 → 1

Hold ratings0 → 0

Sell ratings0 → 0

CLLS analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$61M

↓ 16.7% YoY

Revenue Next Year

$118M

↑ 93.2% YoY

EPS This Year

$-0.92

EPS Next Year

$-0.74

↓ 19.5% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast CLLS EPS of $-0.92 for the current fiscal year, based on estimates from 6 analysts. The CLLS revenue forecast is $61M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

CLLS 股价预测由两类独立数据源支撑：来自 17 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CLLS 的共识目标价为 $9.00（+207.2% 上行空间），分析师共识为 Buy。

CLLS 的短期预测（明日）为 $2.78（-5.00%）。 CLLS 对 2027 年的股价预测均值为 $1。 CLLS 对 2030 年的预测区间为 $1–$1。

Cellectis S.A. 在 NASDAQ 上市，代码 CLLS。CLLS 在 2027 年的整体展望偏积极，在覆盖分析师中约 82% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

常见问题

CLLS 预测 · 8 个问题

根据 17 位华尔街分析师，CLLS 的 12 个月平均目标价为 $9.00，最高 $9.00、最低 $9.00。若有图表，中位目标价可在上方查看。相对当前价 $2.93，隐含约 +207.2% 的上行空间。

CLLS 目标价CLLS 分析师目标价CLLS 12个月目标价目标价 CLLS

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.